BMS submits hep C drugs in the USA
Bristol-Myers Squibb has submitted new drug applications with US regulators for hepatitis C drugs daclatasvir and asunaprevir.
Read MoreAuthor: Katrina Megget
Sun buys Ranbaxy for $4 billion
Sun Pharma has bought Ranbaxy for $4 billion to create the world’s fifth-biggest generic drugmaker.
Read MoreGenomics issues in a new era for pharma
Advances in genomics will change the way pharma discovers, regulates and reimburses new medicines, Amgen’s R&D head in Europe has said.
Read MoreGenomics offers hope to patients
The era of genomics and the possible $1000 genome offers hope to millions of patients with rare diseases, the director of Genetic Alliance UK says.
Read MoreUK to launch early access to drugs plan
UK plans to fast track access to drugs – in some cases up to ten years earlier – are expected to be announced imminently.
Read More- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
